trending Market Intelligence /marketintelligence/en/news-insights/trending/4cP1ex8O3ib6RXxxMCm2CQ2 content esgSubNav
In This List

Regulus Therapeutics receives Nasdaq noncompliance notice

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Regulus Therapeutics receives Nasdaq noncompliance notice

Regulus Therapeutics Inc. received a notice from the Nasdaq Stock Market for failing to meet the exchange's $1 minimum bid price listing requirement.

The company has 180 days to regain compliance.

The notice has no effect on the company's common stock listing at the time.